Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > HIV lipodystrophy causes morbidity and mortality

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Dec 24, 2024 10:37am

28 Views

Post# 36376355

RE:RE:RE:RE:RE:RE:RE:RE:HIV lipodystrophy causes morbidity and mortality

It's all very interesting but my fear is that FDA does'nt see Egrifta has a life and death drug and take the full 4 months to stamp the last batch of the thing. If so they could run the risk of loosing patients to unaproved substitutes.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks